IRIS Accounts Production v23.3.0.418 09953150 director 1.2.22 31.1.23 31.1.23 false true false false true false Ordinary 1.00000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pure099531502022-01-31099531502023-01-31099531502022-02-012023-01-31099531502021-01-31099531502021-02-012022-01-31099531502022-01-3109953150ns16:EnglandWales2022-02-012023-01-3109953150ns15:PoundSterling2022-02-012023-01-3109953150ns11:Director12022-02-012023-01-3109953150ns11:PrivateLimitedCompanyLtd2022-02-012023-01-3109953150ns11:SmallEntities2022-02-012023-01-3109953150ns11:AuditExemptWithAccountantsReport2022-02-012023-01-3109953150ns11:SmallCompaniesRegimeForDirectorsReport2022-02-012023-01-3109953150ns11:SmallCompaniesRegimeForAccounts2022-02-012023-01-3109953150ns11:FullAccounts2022-02-012023-01-3109953150ns11:OrdinaryShareClass12022-02-012023-01-3109953150ns11:RegisteredOffice2022-02-012023-01-3109953150ns6:CurrentFinancialInstruments2023-01-3109953150ns6:CurrentFinancialInstruments2022-01-3109953150ns6:ShareCapital2023-01-3109953150ns6:ShareCapital2022-01-3109953150ns6:RetainedEarningsAccumulatedLosses2023-01-3109953150ns6:RetainedEarningsAccumulatedLosses2022-01-3109953150ns6:LeaseholdImprovements2022-02-012023-01-3109953150ns6:PlantMachinery2022-02-012023-01-3109953150ns6:FurnitureFittings2022-02-012023-01-3109953150ns6:MotorVehicles2022-02-012023-01-3109953150ns6:ComputerEquipment2022-02-012023-01-3109953150ns6:LeaseholdImprovements2022-01-3109953150ns6:PlantMachinery2022-01-3109953150ns6:FurnitureFittings2022-01-3109953150ns6:LeaseholdImprovements2023-01-3109953150ns6:PlantMachinery2023-01-3109953150ns6:FurnitureFittings2023-01-3109953150ns6:LeaseholdImprovements2022-01-3109953150ns6:PlantMachinery2022-01-3109953150ns6:FurnitureFittings2022-01-3109953150ns6:MotorVehicles2022-01-3109953150ns6:ComputerEquipment2022-01-3109953150ns6:MotorVehicles2023-01-3109953150ns6:ComputerEquipment2023-01-3109953150ns6:MotorVehicles2022-01-3109953150ns6:ComputerEquipment2022-01-3109953150ns6:WithinOneYearns6:CurrentFinancialInstruments2023-01-3109953150ns6:WithinOneYearns6:CurrentFinancialInstruments2022-01-3109953150ns6:DeferredTaxation2022-01-3109953150ns6:DeferredTaxation2022-02-012023-01-3109953150ns6:DeferredTaxation2023-01-3109953150ns11:OrdinaryShareClass12023-01-31
REGISTERED NUMBER: 09953150 (England and Wales)














UNAUDITED FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 JANUARY 2023

FOR

CLAIRE DAVIES PHARMA CONSULTING LIMITED

CLAIRE DAVIES PHARMA CONSULTING LIMITED (REGISTERED NUMBER: 09953150)






CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JANUARY 2023




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 4

Report of the Accountants 8

CLAIRE DAVIES PHARMA CONSULTING LIMITED

COMPANY INFORMATION
FOR THE YEAR ENDED 31 JANUARY 2023







DIRECTOR: Mrs C Milligan





REGISTERED OFFICE: 45 Queen Street
Deal
Kent
CT14 6EY





REGISTERED NUMBER: 09953150 (England and Wales)





ACCOUNTANTS: Higson & Co (Deal) Ltd
45 Queen Street
Deal
Kent
CT14 6EY

CLAIRE DAVIES PHARMA CONSULTING LIMITED (REGISTERED NUMBER: 09953150)

BALANCE SHEET
31 JANUARY 2023

2023 2022
Notes £    £    £    £   
FIXED ASSETS
Tangible assets 4 69,233 24,331

CURRENT ASSETS
Stocks 5 12,210 9,660
Debtors 6 4,428 1,840
Cash at bank 148,906 164,390
165,544 175,890
CREDITORS
Amounts falling due within one year 7 16,173 27,864
NET CURRENT ASSETS 149,371 148,026
TOTAL ASSETS LESS CURRENT
LIABILITIES

218,604

172,357

PROVISIONS FOR LIABILITIES 8 10,022 4,585
NET ASSETS 208,582 167,772

CAPITAL AND RESERVES
Called up share capital 9 100 100
Retained earnings 208,482 167,672
SHAREHOLDERS' FUNDS 208,582 167,772

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 January 2023.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 January 2023 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges her responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

CLAIRE DAVIES PHARMA CONSULTING LIMITED (REGISTERED NUMBER: 09953150)

BALANCE SHEET - continued
31 JANUARY 2023


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Statement of Income and Retained Earnings has not been delivered.

The financial statements were approved by the director and authorised for issue on 28 October 2023 and were signed by:





Mrs C Milligan - Director


CLAIRE DAVIES PHARMA CONSULTING LIMITED (REGISTERED NUMBER: 09953150)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JANUARY 2023

1. STATUTORY INFORMATION

Claire Davies Pharma Consulting Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The Financial Statements are presented in round pounds sterling £.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover
Turnover represents invoiced sales of services excluding value added tax. Revenue is recognised once the service has been completed.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Improvements to property - 10% on cost
Plant and machinery - 15% on reducing balance
Fixtures and fittings - 15% on reducing balance
Motor vehicles - 15% on reducing balance
Computer equipment - 33% on cost

Tangible fixed assets are tested for impairment annually.
It is the Company's policy to capitalise items with an estimated useful life in excess of two years, and for amounts in excess of £300.

Stocks
Work in progress is valued at the lower of cost and net realisable value.

Cost is calculated using the first-in, first-out method and includes all purchase, transport, and handling costs in bringing stocks to their present location and condition.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Statement of Income and Retained Earnings, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.


CLAIRE DAVIES PHARMA CONSULTING LIMITED (REGISTERED NUMBER: 09953150)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 JANUARY 2023

2. ACCOUNTING POLICIES - continued
Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Pension costs and other post-retirement benefits
Pension Costs are represented by Company contributions to the director's personal pension scheme.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 1 (2022 - 1 ) .

4. TANGIBLE FIXED ASSETS
Improvements Fixtures
to Plant and and
property machinery fittings
£    £    £   
COST
At 1 February 2022 55,270 - 6,294
Additions - 499 -
At 31 January 2023 55,270 499 6,294
DEPRECIATION
At 1 February 2022 33,418 - 3,937
Charge for year 5,527 69 353
At 31 January 2023 38,945 69 4,290
NET BOOK VALUE
At 31 January 2023 16,325 430 2,004
At 31 January 2022 21,852 - 2,357

CLAIRE DAVIES PHARMA CONSULTING LIMITED (REGISTERED NUMBER: 09953150)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 JANUARY 2023

4. TANGIBLE FIXED ASSETS - continued

Motor Computer
vehicles equipment Totals
£    £    £   
COST
At 1 February 2022 - 1,476 63,040
Additions 56,090 - 56,589
At 31 January 2023 56,090 1,476 119,629
DEPRECIATION
At 1 February 2022 - 1,354 38,709
Charge for year 5,647 91 11,687
At 31 January 2023 5,647 1,445 50,396
NET BOOK VALUE
At 31 January 2023 50,443 31 69,233
At 31 January 2022 - 122 24,331

5. STOCKS
2023 2022
£    £   
Work-in-progress 12,210 9,660

6. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2023 2022
£    £   
Trade debtors 4,428 1,800
Prepayments - 40
4,428 1,840

7. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2023 2022
£    £   
Tax 9,010 13,915
Social security and other taxes 319 334
VAT 5,631 4,179
Other creditors 247 72
Directors' current accounts 246 8,684
Accrued expenses 720 680
16,173 27,864

8. PROVISIONS FOR LIABILITIES
2023 2022
£    £   
Deferred tax 10,022 4,585

CLAIRE DAVIES PHARMA CONSULTING LIMITED (REGISTERED NUMBER: 09953150)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 JANUARY 2023

8. PROVISIONS FOR LIABILITIES - continued

Deferred
tax
£   
Balance at 1 February 2022 4,585
Provided during year 5,437
Balance at 31 January 2023 10,022

9. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 2023 2022
value: £    £   
100 Ordinary 1.00 100 100

10. DIRECTOR'S ADVANCES, CREDITS AND GUARANTEES

During the year the following Directors Loan Accounts subsisted;

Directors Loan Account
A member of key management personnel

During the year the Director advanced the Company £754 (2022:£nil)

During the year the Company repaid the Director £9,192 (2022:£22,626)

As at the year end the Company owed the Director £246 (2022:£8,684)

The loan is interest free and repayable upon demand.

CLAIRE DAVIES PHARMA CONSULTING LIMITED

REPORT OF THE ACCOUNTANTS TO THE DIRECTOR OF
CLAIRE DAVIES PHARMA CONSULTING LIMITED

The following reproduces the text of the report prepared for the director in respect of the company's annual unaudited financial statements. In accordance with the Companies Act 2006, the company is only required to file a Balance Sheet. Readers are cautioned that the Income Statement and certain other primary statements and the Report of the Director are not required to be filed with the Registrar of Companies.

As described on the Balance Sheet you are responsible for the preparation of the financial statements for the year ended 31 January 2023 set out on pages one to ten and you consider that the company is exempt from an audit.

In accordance with your instructions, we have compiled these unaudited financial statements in order to assist you to fulfil your statutory responsibilities, from the accounting records and information and explanations supplied to us.






Higson & Co (Deal) Ltd
45 Queen Street
Deal
Kent
CT14 6EY


28 October 2023